MEDIVISION-MEDICAL : Q3 2013 Investors Update

MediVision Medical Imaging Ltd. +(972) 4-989-4884 +(972) 4-989-4883

 26 Sweden St. Haifa, Israel 34980

 noam@medivision.co.il

Haifa, Israel, February 10th, 2014 - MediVision Medical Imaging Ltd. (the "Company", EuroNext: MEDV1) reports that following the closing of the Share Purchase Agreement dated June 17th 2013 (as detailed in various press releases during 2013), the Company has continued the merger process of MTL Print Ltd ("MTL"), an Israeli private company and reports a successful operational management structure and continued sale and delivery of MTL's wide format printers models NurStar 304 and NurStar 305. MTL is engaged in various activities in the field of R&D and manufacturing of capital equipment in the field of digital wide format printers.

Management of the Company is confident that the merger and various financial activities taken immediately afterwards such as the Convertible loans from Sigma Opportunity Fund II and the continued effort to increase sales in the US and other markets will increase the Company's growth significantly.

1

This Report contains certain forward-looking statements and information relating to the Company that are based on the beliefs of the Management of the Company as well as assumptions made by and
information currently available to the Management of the Company. Such statements reflect the current views of the Company with respect to future events, the outcome of which is subject t o certain risks including but not limited to as listed below and other factors, which may be outside of the Company's control. Shou ld one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results of outcomes may vary materially from those described herein as projected, anticip ated, believed, estimated, expected or intended. Such abovementioned risks include but are not limited to: 1. Failure to consummate the proposed Transaction; 2. Uncertain market acceptance of Company products - The Company's future growth and profitability will depend, in large part, on the acceptance by the market of the Company's existing and proposed products. This acceptance will be substantially dependent on educating the market as to full capabilities, distinctive characteristics, perceived benefits and efficacy of the Company's existing and proposed products. In addition, the future success of the Company's products will depend on their acceptance by customers and on such customers' willingness and ability to purchase such products. There can be no assurance that the Company's produc ts will receive the necessary market acceptance. Failure of the Company's existing and/or proposed products to gain market acceptance could have a material adverse effect on the Company's business, financial cond ition and results of operations. 3. Financial Requirements - The implementation of the Company's plans underlying the Transaction requires additional funding,. There is no certainty that the required funds will be available to the Company at all or upon terms acceptable to the company.

distributed by